In 2017, life sciences organizations will need to find ways to simultaneously manage costs, pricing, and new regulation – all while delivering clinical innovation (1), according to a recent article by Deloitte. The pressures are creating a new normal in this sector and causing disruption in the industry. From the changes in new legislation and regulations to the shift in patient- and customer-centered models, the industry already looks different today than it did just a few years ago.
The changing landscape and pressure for innovation and cost-management is a significant challenge for many life sciences companies. Couple that with the fact that maintaining a competitive advantage requires some degree of capital investment, and suddenly staying afloat amid waves of change becomes increasingly more complex.
There is a way to make capital investments more palatable during a time of uncertainty and transformation: by turning to lease-financing.
As you consider all angles for navigating the new normal of this environment, be cognizant to include a strategy for handling resulting capital investments.
Facing change is complex enough – allow us to help with capital investments along the way. At First American, we are helping life sciences companies achieve their growth goals through creative financing solutions.
(1) Deloitte. (2017). "The forecast for life sciences in 2017"